Kenya PPB: 67 Fake Medicine Product Recalls in Intensified Crackdown

• The Kenyan government has intensified its crackdown on illegal pharmaceutical outlets and unscrupulous pharmacists selling fake and substandard medicines.
• Since January 2025, 67 products have been recalled from the market, and illegal outlets have been shut down, leading to arrests and prosecutions.
• The Pharmacy and Poisons Board (PPB) is rolling out a Track and Trace System in collaboration with the Digital Health Agency to enhance medicine authenticity.
• Public Health PS Mary Muthoni urged Kenyans to buy medicines only from licensed entities and avoid unverified online sources.
• Strategic discussions are ongoing with the Kenya Healthcare Federation to foster public-private partnerships, including the upcoming KEPHIC 2026 conference.

Since January 2025, a total of 67 products have been subjected to Kenya PPB fake medicine product recalls, effectively removing them from circulation.

The Kenyan government has significantly escalated its efforts against the illicit trade of pharmaceutical products, targeting unscrupulous pharmacists and unauthorized outlets responsible for distributing fake and substandard medicines. This intensified crackdown aims to protect the public from potentially harmful drugs circulating in the market. Public Health and Professional Standards Principal Secretary Mary Muthoni recently underscored the urgency of this issue during a high-level roundtable discussion with the Kenya Healthcare Federation (KHF), advocating for enhanced collaboration among all stakeholders to curb the widespread availability of substandard and falsified medical products across the nation.

PS Muthoni revealed that regulatory actions have already yielded substantial results. Since January 2025, a total of 67 products have been subjected to Kenya PPB fake medicine product recalls, effectively removing them from circulation. Concurrently, authorities have moved to shut down numerous illegal pharmaceutical outlets, leading to the arrest and prosecution of individuals involved in these illicit operations. This robust enforcement drive by the Pharmacy and Poisons Board Kenya is a direct response to the persistent threat posed by counterfeit and non-compliant medicines, which PS Muthoni characterized as a global public health concern demanding constant vigilance and coordinated intervention.

The ongoing enforcement measures highlight the government's commitment to safeguarding public health by ensuring the integrity of the pharmaceutical supply chain. The focus remains on eradicating sources of Kenya substandard falsified medicines and holding accountable those who compromise patient safety for commercial gain.

To bolster the quality and safety of medicines available to the public, the Pharmacy and Poisons Board (PPB) is actively implementing new regulatory safeguards. A key initiative is the rollout of the Kenya Track and Trace System medicines, developed in partnership with the Digital Health Agency. This system is designed to enhance oversight and authenticity verification throughout the pharmaceutical distribution network, making it more difficult for counterfeit products to enter the legitimate supply chain.

Public Health PS Mary Muthoni also emphasized the critical role of consumer awareness in combating this menace. She strongly advised Kenyans to exercise extreme caution when purchasing medicines, particularly from informal channels such as local chemists or pharmacies that may not be officially sanctioned. Muthoni reiterated that all pharmaceutical purchases should exclusively occur through licensed entities to guarantee product authenticity and safety.

Furthermore, PS Muthoni issued a stern warning against procuring medicines from unverified online platforms and social media pages, urging citizens to instead patronize only licensed pharmacies and authorized retail outlets. This guidance is crucial for individuals seeking to avoid the risks associated with Kenya substandard falsified medicines and to ensure they receive genuine, effective treatments.

Beyond immediate enforcement, strategic discussions are underway to foster broader public-private partnerships aimed at strengthening the pharmaceutical sector. PS Muthoni engaged with the Kenya Healthcare Federation to position the upcoming Kenya Public Health International Conference (KEPHIC) 2026 as a pivotal national forum for such collaborations. This conference, scheduled for October 27–29, 2026, at the Kenyatta International Convention Centre, is envisioned as a platform to address systemic challenges and opportunities within the health landscape.

Dr. Anne Musuva, Acting CEO of the Kenya Healthcare Federation, affirmed the industry's dedication to supporting the advancement of Universal Health Coverage (UHC). This commitment includes ensuring widespread access to safe, high-quality, and affordable health products and technologies. The collaborative spirit demonstrated by both government and industry stakeholders is vital in building a resilient pharmaceutical ecosystem capable of effectively combating the proliferation of Kenya substandard falsified medicines and protecting the well-being of all citizens.

This development signals intensified regulatory scrutiny and enforcement risk for pharmaceutical companies and distributors in Kenya. Legal and compliance teams should advise clients to review their licensing, supply chain integrity, and product authenticity protocols to mitigate exposure to penalties and product recalls, especially in light of the ongoing crackdown and the rollout of the Track and Trace System.

Source: Reporting based on official government statements